trimetrexate has been researched along with Adenocarcinoma in 12 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 9.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "Twenty-five samples of fresh malignant cells of patients with acute leukemia (16 with acute myeloblastic leukemia, five with acute lymphoblastic leukemia, and four with chronic myelocytic leukemia in blast crisis) and of two patients with colon carcinoma were exposed for 1 hr to different concentrations of methotrexate (MTX) or trimetrexate (TMQ)." | 7.67 | Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. ( Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL, 1987) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 5.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days." | 5.07 | Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study. ( Hantel, A; Macdonald, JS; Pollock, T; Pugh, RP; Richman, SP; Tangen, CM, 1994) |
| "Within three repeated 7-day incubation periods with either methotrexate (MTX) or trimetrexate (TMTX), human colon adenocarcinoma cells (HCT-8) developed high levels of resistance to these drugs, as evidenced by approximately 20- and 50-fold increases, respectively, in the median effective doses." | 3.68 | Rapid development of resistance to antifolates in vitro: possible clinical implication. ( Aschele, C; Bertino, JR; Nicolin, A; Rosso, R; Sobrero, A, 1991) |
| "Twenty-five samples of fresh malignant cells of patients with acute leukemia (16 with acute myeloblastic leukemia, five with acute lymphoblastic leukemia, and four with chronic myelocytic leukemia in blast crisis) and of two patients with colon carcinoma were exposed for 1 hr to different concentrations of methotrexate (MTX) or trimetrexate (TMQ)." | 3.67 | Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. ( Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL, 1987) |
| " The dosage of TMTX was reduced to 8 mg/m(2) daily for 5 days for those who had received prior radiotherapy." | 2.69 | Phase II trial of trimetrexate for patients with advanced gastric carcinoma: an Eastern Cooperative Oncology Group study (E1287). ( Asbury, RF; Greenberg, BR; Haller, DG; Lipsitz, S; Qazi, R; Ramanathan, RK, 1999) |
| " The base model employed for modeling dose-response effect is the four parameter Hill equation [1]." | 1.32 | A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. ( Brun, Y; Greco, WR; Slocum, HK; White, DB; Wrzosek, C, 2003) |
| "Thrombocytopenia was dose limiting, but highly variable among patients at a given dose level; other toxicity was mild and uncommon." | 1.27 | Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. ( Cassidy, C; Chou, TC; Fanucchi, MP; Fleisher, M; Lokos, G; Niedzwiecki, D; Vidal, P; Walsh, TD; Williams, L; Young, CW, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, CD | 1 |
| Chansky, K | 1 |
| Christman, KL | 1 |
| Hundahl, SA | 1 |
| Issell, BF | 1 |
| Van Veldhuizen, PJ | 1 |
| Budd, GT | 1 |
| Abbruzzese, JL | 1 |
| Macdonald, JS | 2 |
| Faessel, HM | 2 |
| Slocum, HK | 3 |
| Rustum, YM | 2 |
| Greco, WR | 3 |
| White, DB | 1 |
| Brun, Y | 1 |
| Wrzosek, C | 1 |
| Hantel, A | 1 |
| Tangen, CM | 1 |
| Richman, SP | 1 |
| Pugh, RP | 1 |
| Pollock, T | 1 |
| Ramanathan, RK | 1 |
| Lipsitz, S | 1 |
| Asbury, RF | 1 |
| Qazi, R | 1 |
| Greenberg, BR | 1 |
| Haller, DG | 1 |
| Sobrero, A | 2 |
| Aschele, C | 1 |
| Rosso, R | 2 |
| Nicolin, A | 2 |
| Bertino, JR | 4 |
| Carlson, RW | 1 |
| Doroshow, JH | 1 |
| Odujinrin, OO | 1 |
| Flam, MS | 1 |
| Malec, M | 1 |
| Lamborn, KR | 1 |
| Romanini, A | 1 |
| Russello, O | 1 |
| Sobrero, AF | 1 |
| Fanucchi, MP | 1 |
| Walsh, TD | 1 |
| Fleisher, M | 1 |
| Lokos, G | 1 |
| Williams, L | 1 |
| Cassidy, C | 1 |
| Vidal, P | 1 |
| Chou, TC | 1 |
| Niedzwiecki, D | 1 |
| Young, CW | 1 |
| Rodenhuis, S | 1 |
| McGuire, JJ | 1 |
| Sawicki, WL | 1 |
4 trials available for trimetrexate and Adenocarcinoma
| Article | Year |
|---|---|
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2010 |
Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Aged; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Trimetrexate | 1994 |
Phase II trial of trimetrexate for patients with advanced gastric carcinoma: an Eastern Cooperative Oncology Group study (E1287).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease Progression; Femal | 1999 |
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Evaluation; Drugs, Investigational; Female; Humans; Male | 1990 |
8 other studies available for trimetrexate and Adenocarcinoma
| Article | Year |
|---|---|
Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplas | 2003 |
A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example.
Topics: Adenocarcinoma; Algorithms; Antimetabolites; Antineoplastic Agents; Cell Division; Cell Line, Tumor; | 2003 |
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; D | 1999 |
Rapid development of resistance to antifolates in vitro: possible clinical implication.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; | 1991 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un | 1989 |
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Topics: Adenocarcinoma; Animals; Cattle; Cell Adhesion; Colonic Neoplasms; Colony-Forming Units Assay; Cultu | 1986 |
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Deoxyuridine; Drug E | 1987 |
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Topics: Adenocarcinoma; Colonic Neoplasms; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; | 1987 |